News | October 15, 2021
Expect normal quarter in Q2FY22: Emkay
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The company plans to raise US $ 15 million
Since its inception, the company has either acquired or taken a majority stake in five companies
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The Pune centre expands its presence beyond Bangalore and Hyderabad
The applicants will only have to get their Good Manufacturing Practices certification validated every five years to retain their licence
The company plans to expand its portfolio in regulated markets aggressively
Subscribe To Our Newsletter & Stay Updated
